References
- Thompson GR, Cadera J, Patterson TF. Overview of antifungal agents. Clin Chest Med. 2009;30(2):203–215.
- Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. Drug Ther. 1994;330(4):263–272.
- Nett JE, Andes DR. Antifungal agents. Spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin North Am. 2016;30(1):51–83.
- Baxter CG, Marshall A, Roberts M. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother. 2011;66(9):2136–2139.
- Stevens DA. Safety evaluation of chronic fluconazole therapy. Fluconazole pan-American study group. Chemotherapy. 1997;45(3):371–377.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
- Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med. 2008;29(2):198–210.
- Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunopharmacology of Modern Antifungals. Immunocompromised Hosts. 2008;47(2):226–235.
- Alavi S, Abadi M. Prolonged vincristine toxicity induced by concurrent posaconazole in a child with T-cell acute lymphoblastic leukemia. Iran J Med Sci. 2013;38(2):135–136.
- Mantadakis E, Amoiridis G, Kondi A, et al. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol. 2007;29(2):130.
- Mora E, Lavoie Smith EM, Donohoe C, et al. Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res. 2016;6(11):2416–2430.
- Nikanjam M, Sun A, Albers M, et al. Vincristine associated neuropathy with antifungal usage: a kaiser northern california experience. J Pediatr Hematol Oncol. 2018;40(5):e273–e277.
- https://www.uptodate.com/drug-interactions
- Pasikhova Y, Ludlow SP. Fluconazole associated agranulocytosis and thrombocytopenia. Int J Clin Pharm. 2014;36(2):268–270.